Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK

Kirby, Andrew; Graham, Robert H.; Williams, Nicola; Wootton, Mandy; Broughton, Caroline; Alanazi, Mishaal; Anson, James; Neal, Timothy; Parry, Christopher M.

doi:10.1093/jac/dkq009

Cited by 24 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most previous studies have focused on hVISA and VISA strains isolated from blood [24,25]. Recently, Hu and colleagues found that hVISA and VISA strains were identified from diverse infection sites, predominantly from sputum (56.3%), followed by pus (18.8%), blood (8.8%), secretions (6.3%), drainage (3.8%), and other (6.3%) [26].…”

Section: Discussionmentioning

confidence: 99%

Vancomycin susceptibility trends of methicillin-resistant Staphylococcus aureus isolated from burn wounds: a time for action

Zorgani

Elahmer

Abaid³

et al. 2015

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin poses a threat for patients in burn units throughout the world. This study aimed to investigate the reduced susceptibility to vancomycin of MRSA isolated from wounds of patients admitted to the Burns and Plastic Surgery Centre in Tripoli, Libya. Methodology: All isolates were initially identified by chromagen medium then confirmed by PCR. The minimum inhibition concentration (MIC) was determined by E-test glycopeptide resistance detection (GRD). Results: During the study, 210 isolates were obtained from 560 patients representing 132 (62.9%) and 78 (37.1%) of total samples received during years 2009 and 2010, respectively. MIC levels for vancomycin ranged from 0.5 to 2 µg/ml during the study, 13% of isolates displayed MIC of 1.5 µg/ml and 9% of the isolates displayed 2 µg/ml. Although MRSA isolates decreased dramatically during 2010 (37.1%) compared to 2009 (62.9%), overall, there was a significant increase in the proportion of MRSA isolates exhibiting higher vancomycin MICs during 2010 compared to 2009 (P = 0.0155). There was a significant increase of MICs at 1 µg/ml during 2010 compared with 2009 (P = 0.36). No vancomycin intermediate or resistant strains were found. Conclusion: There was a significant increase in the proportion of MRSA isolates exhibiting higher vancomycin MICs. We recommend that MRSA isolates should be monitored. Furthermore, implementation of infection control measures is urgently needed to prevent the spread of MRSA.

show abstract

Section: Discussionmentioning

confidence: 99%

Vancomycin susceptibility trends of methicillin-resistant Staphylococcus aureus isolated from burn wounds: a time for action

Zorgani

Elahmer

Abaid³

et al. 2015

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Since then, clinical isolates of S. aureus with decreased susceptibility to vancomycin have been reported in many countries, including the United Satates [3,4], Canada [5], China [6], South Korea [6], United Kingdom [7,8], Italy [9], and France [10], and their occurrence has become a major concern throughout the world. Additionally, in 2002, the first vancomycin-resistant S. aureus (VRSA) strain was reported in the Jung Wook Kim, et al : Molecular Characteristics and Resistance Profiles of VISA 89…”

Section: Introductionmentioning

confidence: 99%

Molecular Typing and Resistance Profiles of Vancomycin-IntermediateStaphylococcus aureusin Korea: Results from a National Surveillance Study, 2007-2013

et al. 2016

View full text Add to dashboard Cite

“…The strains positive with agar screening method were subjected to macro Etest and subpopulation analysis. These methods are reliable and sensitive to detect hGISA (Kirby et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

“…In the past few years, GRSA, GISA and hGISA have increasingly been reported (Kirby et al, 2010). hGISA strains are defined as for which vancomycin MICs are 1 to 4 µg mL −1 but which contain subpopulations that can grow on agar plates supplemented with 4 mg of vancomycin per liter (Satola et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

PREVALENCE OF HETEROGENEOUS GLYCOPEPTIDE INTERMEDIATE RESISTANCE IN METHICILLIN-RESISTANT <i>STAPHYLOCOCCUS AUREUS</i>

Chaudhary¹

2013

American Journal of Infectious Diseases

View full text Add to dashboard Cite

Multidrug resistant Methicillin-Resistant Staphylococcus aureus (MRSA) is a major cause of nosocomial and community acquired infections and is on the rise. The aim of this investigation was to explore the prevalence of MRSA and heterogeneous Glycopeptide Intermediate Staphylococcus aureus (hGISA) in various clinical samples, to investigate the various antibiotic resistant determinant genes among these strains collected from north and west Indian hospitals and to evaluate the response of various drugs to these strains. A total of 413 clinical specimens collected from different hospitals were processed for the screening of S. aureus and MRSA. All the MRSA strains were further screened for hGISA on Mueller-Hinton agar containing 8 µg mL −1 teicoplanin or 6 µg mL −1 vancomycin. hGISA confirmed by the E-test method with a dense inoculum and a simplified method of population analysis. Susceptibility study was conducted according to the Clinical and Laboratory Standards Institute (CLSI) methods. Among 211/413 S. aureus clinical isolates, 61.6% (130/211) of the isolates were confirmed to be MRSA which included maximum isolates from pus, blood, urine, wound swab and ear swab samples in decreasing order. hGISA strains were found in 8/130 (6.1%) isolates. Vancoplus, a novel antibiotic adjuvant entity was found to be susceptible in 96.1 to 97.8% MRSA strains and showed intermediate response in 2.2 to 3.8% of isolates. Linezolid appeared to be second most active antibiotic with 48.0 to 81.2% susceptibility, followed by teicoplanin (41.3 to 56.2% susceptibility). There was 8.7 to 9.6% resistance observed in Linezolid which was increased to 48% in teicoplanin, to >60% in daptomycin and >75% in vancomycin. Interestingly, none of the isolates were susceptible to ceftriaxone and cefoperazone plus sulbactam. From the above study it can be concluded that prevelance of MRSA has reached a significant level and Vancoplus is the most effective drug in MRSA as well as hGISA organisms in comparison to comparator drugs.

show abstract

Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK

Abstract: Laboratory strategies to reduce morbidity associated with hGISA should focus on testing for hGISA in bacteraemic (rather than colonizing) MRSA isolates in patients with recurrent S. aureus bacteraemia following glycopeptide exposure.

Cited by 24 publications

References 11 publications

Vancomycin susceptibility trends of methicillin-resistant Staphylococcus aureus isolated from burn wounds: a time for action

Vancomycin susceptibility trends of methicillin-resistant Staphylococcus aureus isolated from burn wounds: a time for action

Molecular Typing and Resistance Profiles of Vancomycin-IntermediateStaphylococcus aureusin Korea: Results from a National Surveillance Study, 2007-2013

PREVALENCE OF HETEROGENEOUS GLYCOPEPTIDE INTERMEDIATE RESISTANCE IN METHICILLIN-RESISTANT <i>STAPHYLOCOCCUS AUREUS</i>

Contact Info

Product

Resources

About